# Stipple Bio

> Stipple Bio discovers tumor-specific epitopes with its Pointillist platform to develop precision oncology antibodies.

## Why it is interesting

Epitope-level (not just protein-level) tumor targeting could widen the therapeutic window for solid tumors — a16z backed from seed through an oversubscribed $100M Series A.

## Profile

- **Stage:** other
- **Status:** private
- **Industries:** healthtech, biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Series A (Apr 2026): $100M co-led by a16z Bio+Health, RA Capital, Nextech Invest — GlobeNewswire, BioSpace
- Precision oncology using Pointillist epitope-discovery platform; lead asset STP-100 entering clinic
- Co-investors: no additional institutional investors disclosed in public sources reviewed 2026-07-24

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz

## Related articles

- https://venturecapitaltracker.com/2026-a16z-hot-portfolio-companies

---
Source: https://venturecapitaltracker.com/startup/stipple-bio